Skip to content

Evaluation of Dermatomal Distribution in the Erector Spinae Plane (ESP) Block

Evaluation of Dermatomal Distribution in the Erector Spinae Plane (ESP) Block

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03831581
Enrollment
16
Registered
2019-02-06
Start date
2018-01-01
Completion date
2018-10-31
Last updated
2023-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Chronic, Pain, Postoperative

Keywords

Erector Spinae Plane, Erector Spinae Plane Block

Brief summary

Interventional study that evaluate dermatomal distribution and its demographic determinants in patients who underwent to Erector Spinae Plane (ESP) block

Detailed description

Interventional study that evaluate dermatomal distribution with pinprick and cold, and its demographic determinants in patients who underwent to Erector Spinae Plane (ESP) block with 20 ml of bupivacaine 0.5% at the thoracic level in patients with pain in the thorax and upper abdomen.

Interventions

PROCEDUREErector Spinae Plane Block

In patients with chest pain, ultrasound-guided Erector Spinae Plane Block block was performed at T5 transverse process in the cephalo-caudal direction with Tuohy 18 gauge needle in plane until the needle tip was located in the interfascial plane between the transverse process and the erector spinae muscles, 20 ml of bupivacaine 0.5% was administered and a catheter was inserted if indicated.

Sponsors

Universidad de Antioquia
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Assignment interventional

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Patients older than 18 years, in the acute / chronic pain service that presents pain in the thoracic region and / or upper hemiabdomen.

Exclusion criteria

* Women in pregnancy * Patients with less than 50 Kg of weight * Dissent of informed consent

Design outcomes

Primary

MeasureTime frameDescription
Dermatomes with sensitive block60 minutesNumber (average) of dermatomes with sensitive block with pinprick and cold achieved at 60 minutes after the Erector Spinae Plane (ESP) block with 20 ml of bupivacaine 0.5%. Also, observe the distribution pattern.

Secondary

MeasureTime frameDescription
Adverse events60 minutes and 24 hoursFrequency of adverse events (hypotension, pneumothorax, neurological deficit, bradycardia) after the Erector Spinae Plane (ESP) block.
Success rate60 minutes and 24 hoursSuccess rate (Blocking of at least 2 continuous dermatomes at the puncture site measured with pinprick and cold)
Degree of satisfaction60 minutes and 24 hoursDegree of satisfaction evaluated with the Likert scale of 4 points (1 dissatisfied, 2 slightly dissatisfied, 3 slightly satisfied, 4 satisfied).
weight60 minutesweight in kilograms and its correlation with the main result The variables were grouped in means (standard deviation) for continuous variables and frequencies (percentages) for categorical variables.
Height60 minutesHeight in meters and its correlation with the main result The variables were grouped in means (standard deviation) for continuous variables and frequencies (percentages) for categorical variables.
Age60 minutesAge in years and its correlation with the main result The variables were grouped in means (standard deviation) for continuous variables and frequencies (percentages) for categorical variables.
Visual Analogue Scale (VAS)60 minutes and 24 hoursChange From Baseline in Pain Scores on the Visual analogue scale (VAS) from 1 to 10 at 60 minutes and 24 hours after the ESP block.

Countries

Colombia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026